Key result
Exenatide therapy over 82 weeks produced durable reductions in HbA1c (-1.3%) and progressive weight loss (-5.3 kg) in patients with type 2 diabetes inadequately controlled on metformin.
Why the study?
Does exenatide improve glycaemic control and reduce body weight in patients with type 2 diabetes failing to achieve glycaemic control with metformin?
RCT (n=150)
Open-label
Does exenatide improve glycaemic control and reduce body weight in patients with type 2 diabetes failing to achieve glycaemic control with metformin?
Exenatide provides durable improvements in glycaemic control and progressive weight loss over 82 weeks in patients with type 2 diabetes inadequately controlled on metformin.
No takes yet. Share an insight, caveat, or question.
May support exenatide add-on in metformin failure; leaves open randomized confirmation of durability and outcomes.
Ratner et al. (2006) conducted an RCT in Type 2 diabetes mellitus (n=150). Exenatide was evaluated on Haemoglobin A1c (HbA1c) reduction from baseline. Exenatide therapy over 82 weeks produced durable reductions in HbA1c (-1.3%) and progressive weight loss (-5.3 kg) in patients with type 2 diabetes inadequately controlled on metformin.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: